Latest Minneapolis Heart Institute Foundation Stories
Minneapolis Heart Institute Foundation is the first research center in the USA to report implant of a TMVR Device ROSEVILLE, Minn., April 13, 2015 /PRNewswire/ -- Tendyne Holdings,
The Minneapolis Heart Institute Foundation (MHIF) today announced its first implant of the world’s smallest pacemaker: the Medtronic Micra™ Transcatheter Pacing System (TPS) in the Midwest. The device was implanted by Dr. Charles Gornick as part of the global pivotal clinical trial.
Data reported by the Hearts Beat Back: The Heart of New Ulm Project reinforce the positive influence of lifestyle factors in mitigating risks that potentially increase the likelihood of heart disease and other health problems.
A clinical decision support tool helped physicians identify patients at high risk of bleeding complications prior to undergoing a coronary intervention procedure and helped guide the use of bleeding avoidance strategies, leading to less complications and a shorter hospital stay.
Even though young athletes are required to receive health screens to be cleared to play sports, those tests failed to detect important cardiovascular abnormalities in cleared players, and many were allowed to play despite suspicions of dangerous cardiovascular conditions.
Even though a newly recognized cardiomyopathy, which mainly impacts women, is typically treatable, Tako-tsubo cardiomyopathy can also be deadly when compounded by other co-morbidities, such as heart failure.
The belief among medical professionals in the 1950s that the mortality rate for type A acute aortic dissection during the initial 24 hours was one to two percent per hour appears to hold true in the contemporary era of treatment, based on a review of the large-scale IRAD registry being presented March 9 at the American College of Cardiology (ACC) Scientific Sessions.
A pre-procedure bleeding risk score can accurately identify high-risk, high-cost patients and may provide an opportunity to employ bleeding avoidance strategies to improve patient outcomes and reduce total costs related to percutaneous coronary intervention (PCI) procedures.
A population-wide community and clinical prevention program involving 10,000 adults meaningfully reduced the cardiovascular (CV) risk profile among a substantial portion of the population as indicated by those participating in screenings.